न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 7.5mg - capsule - 7.5 mg - active: lenalidomide 7.5mg excipient: brilliant blue fcf croscarmellose sodium erythrosine gelatin lactose magnesium stearate microcrystalline cellulose sunset yellow fcf titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

intervet international bv - equine influenza-virus strains: a/equine-2/south africa/4/03, a/equine-2/newmarket/2/93, tetanus toxoid - equine influenza virus + clostridium - horses - active immunisation of horses from six months of age against equine influenza to reduce clinical signs and virus excretion after infection, and active immunisation against tetanus to prevent mortality.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

te arai biofarma limited - cinacalcet hydrochloride 33.075mg equivalent to 30 mg cinacalcet - film coated tablet - 30 mg - active: cinacalcet hydrochloride 33.075mg equivalent to 30 mg cinacalcet excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry green 85f21867 povidone sodium starch glycolate starch - latest regulatory activity

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

te arai biofarma limited - cinacalcet hydrochloride 66.15mg equivalent to 60 mg cinacalcet - film coated tablet - 60 mg - active: cinacalcet hydrochloride 66.15mg equivalent to 60 mg cinacalcet excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry green 85f21867 povidone sodium starch glycolate starch - latest regulatory activity

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

te arai biofarma limited - cinacalcet hydrochloride 99.225mg equivalent to 90 mg cinacalcet - film coated tablet - 90 mg - active: cinacalcet hydrochloride 99.225mg equivalent to 90 mg cinacalcet excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry green 85f21867 povidone sodium starch glycolate starch - latest regulatory activity

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 10mg - capsule - 10 mg - active: lenalidomide 10mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose sunset yellow fcf tartrazine titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 15mg - capsule - 15 mg - active: lenalidomide 15mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose tartrazine titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 25mg - capsule - 25 mg - active: lenalidomide 25mg excipient: croscarmellose sodium gelatin black sw-9007 printing ink lactose magnesium stearate microcrystalline cellulose titanium dioxide water - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 5mg - capsule - 5 mg - active: lenalidomide 5mg excipient: brilliant blue fcf croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose sunset yellow fcf titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; hyprolose; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.